Tag Archives: Neurodegenerative Diseases

More on the Possible Role of Neuroinflammation in Frontotemporal Dementia (Bazian / Brain)

Posted on March 22, 2020 by Dementia and Elderly Care News

Summary Inflammation in the brain has been found to be present alongside (“co-localised” with) protein clusters in patients with frontotemporal dementia, suggesting that neuroinflammation may be involved as a potential cause of frontotemporal dementia. “The researchers found that both the … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, UK, Universal Interest | Tagged Association of British Neurologists, Bazian, Behavioural Frontotemporal Dementia (bvFTD), Behavioural Variant Frontotemporal Dementia (bvFTD), Behind the Headlines, Biomarker Development, Biomarkers, Biomarkers for Inflammation, Brain (Journal), Brain Autopsies, Brain Inflammation, C-PK-11195, C-PK-11195 (Biomarker for Inflammation), Cambridge Brain Bank, Cambridge Centre for Parkinson-Plus, Cambridge University Hospitals NHS Foundation Trust, Consiglio Nazionale delle Ricerche (CNR), Critical Appraisals, Degenerative Tauopathy, Department of Clinical Neurosciences: Cambridge University, Department of Neurology: Walton Centre (Liverpool), Department of Pathology: Cambridge University Hospitals NHS Foundation Trust, Department of Psychiatry: University of Cambridge, Division of Anaesthesia: University of Cambridge, Early-Onset Dementia, F-AV-1451, F-AV-1451 (Biomarker for Protein Clusters), Fronto-Temporal Dementia (FTD), Frontotemporal Dementia, Frontotemporal Dementia (FTD), FTD: Fronto-Temporal Dementia, FTLD-Pick’s, FTLD-TDP (A), FTLD-TDP (C), FTLD-TDP (Types A and C), FTLD-TDP-43, Immune Cells (Microglia), Inflammation, Inflammation and Neurodegenerative Diseases, Istituto di Bioimmagini e Fisiologia Molecolare (IBFM): Consiglio Nazionale delle Ricerche (CNR), Italy, Lundbeck Foundation (Denmark), Medical Research Council (MRC), Medical Research Council Cognition and Brain Sciences Unit: University of Cambridge, Microglia, Monoamine Oxidase (MAO), National Institute of Health Research, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuroinflammation, Neuroinflammation and Frontotemporal Dementia, Neuroinflammation and Protein Aggregation, Neuromelanin, NIHR Dementias and Neurodegenerative Diseases Research Network, Non-Amyloid-β Protein Aggregation, Non-Fluent Variant Primary Progressive Aphasia (nfvPPA), Patrick Berthoud Charitable Trust, PET Scans, Pick’s Disease (Frontotemporal Dementia), Positron Emission Tomography (PET), Protein Aggregation, Protein Clusters, Semantic Variant Primary Progressive Aphasia (svPPA), Tauopathy, TDP-43, TDP-43 Pathology, TDP-43 Protein, TDP-43 Proteinopathy, University of Cambridge, Variants of Primary Progressive Aphasia (PPA), Wellcome Trust, Wolfson Brain Imaging Centre: University of Cambridge | Leave a comment

Cerebral Amyloid Angiopathy (JGCR)

Posted on March 5, 2020 by Dementia and Elderly Care News

Summary Cerebral Amyloid Angiopathy (CAA) is characterised mainly by impaired perceptual speed, episodic memory, semantic memory, attention and executive function. It has much in common with global cognitive impairment, and diagnosis may overlap with that for Alzheimer’s Disease or other … Continue reading →

Posted in Depression, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Quick Insights, Universal Interest | Tagged Ageing Population, Amyloid, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β Protein, Boston Radiological Criteria for Probable CAA, Cerebral Amyloid Angiopathy, Cerebral Amyloid Angiopathy (CAA), Cerebral Amyloid Angiopathy (CAA): Clinical Manifestations, Cerebral Amyloid Angiopathy (CAA): Psychiatric Manifestations, Cerebral Amyloid Angiopathy (CAA): Psychopathology, Cerebral Amyloid Angiopathy: Neuropsychiatric Patterns, Cerebral Amyloid Angiopathy: Psychiatric Presentations in Old Age, Cognitive Impairment, Computed Tomography (CT) Scan, Dementia and Cognitive Impairment, Differential Diagnosis, Impulsivity, Journal of Geriatric Care and Research (JGCR), Magnetic Resonance Imaging (MRI) Scan, Neurodegenerative Diseases, Neurodegenerative Disorders, New Zealand, Waitemata District Health Board (Auckland) | Leave a comment

Digital Technology for Early Detection of Neurodegenerative Disease (BBC News / EDoN)

Posted on February 15, 2020 by Dementia and Elderly Care News

Summary The Early Detection of Neurodegenerative Diseases (EDoN) initiative, with backing from Alzheimer’s Research UK, is working to develop wearable devices which will collect data to help detect the early stages of Alzheimer’s Disease and other neurodegenerative diseases. Full Text … Continue reading →

Posted in Alzheimer’s Research UK, BBC News, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, UK, Universal Interest | Tagged Accelerating Detection of Disease Programme, Alan Turing Institute, Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Research UK (ARUK), Artificial Intelligence (AI), ARUK: Alzheimer’s Research UK, Asymptomatic Alzheimer’s Disease, Automatic Speech Analysis, BBC Health News, BBC Technology News, Behavioural Biomarkers, Benefits of Early Detection, Big Data, Bill and Melinda Gates Foundation, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, CrawfordWorks, David Cameron, David Cameron: Former Prime Minister, Digital Biomarkers, Digital Diagnostic Tools, Digital Fingerprints, Digital Technology, Digital Technology and Innovation, Early Detection of Alzheimer’s Disease, Early Detection of Disease, Early Detection of Neurodegenerative Diseases, Early Detection of Neurodegenerative Diseases (EDoN), Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnosis of Dementia, Early Recognition of Alzheimer’s Disease Using Digital Technology, Early Recognition of Neurodegenerative Diseases Using Digital Technology, EDoN Clinical Support Group, EDoN Cohorts and Biomarkers Working Group, EDoN Digital Platform Working Group, EDoN Digital Support Group, EDoN Digital Toolkit, EDoN Digital Tools Working Group, EDoN Fingerprint Analytics Working Group, EDoN White Paper, Ethical Considerations, Ethical Sharing of Data Between Organisations, Fingerprint Analytics, Gait: an Integrative Measure of Health, Heart Rate, Iceland Foods Charitable Foundation, Information Technology, International and Independent External Advisory Board, Investment in Information Technology, Machine Learning Models, Medopad, Mild Cognitive Impairment (MCI), Mindstrong Health, MRC Harwell Institute, National Hospital for Neurology and Neurosurgery: University College London, National Physical Laboratory, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Newcastle University, Non-Invasive Biomarkers, Optimising Benefits of Digital Technology, Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Dementia and Associated Lifestyle Changes, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Preclinical Phase of Dementia, Prodromal Alzheimer's Disease, Prodromal Dementia, Rates of Conversion From Mild Cognitive Impairment to Dementia, Research Informatics, Sleep Patterns, Smart Phone apps, Smart Sensors, Smart Watches, Target Discovery and Preclinical Validation, Tencent, The Rt Hon David Cameron: Chair of EDoN Board, The Rt Hon David Cameron: President of Alzheimer’s Research UK, Timely / Preclinical Neurodegenerative Diseases Diagnosis, Timely Screening / Preclinical Neurodegenerative Disease, University College London, University of Cambridge, University of Exeter, University of Oxford Big Data Institute, Walking Speed: a Behavioural Biomarker for Neurocognitive and Physical Decline, Wearable Devices, Wearable Monitoring Equipment, Wearable Sensors, Wearable Technology, Wearables (Technology) | Leave a comment

Biogen’s Aducanumab: Possibly the First Viable Drug Treatment of Alzheimer’s Disease? (BBC News)

Posted on October 24, 2019 by Dementia and Elderly Care News

Summary There were early hopes that the drug Aducanumab (from Biogen) might be able to slow down the build-up of amyloid protein in the brain, but trials were halted in March 2019 due to “disappointing” trial results. Subsequent re-analysis of … Continue reading →

Posted in BBC News, Community Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Aducanumab, Aducanumab (Biogen), Aducanumab: Recombinant Human Monoclonal Antibody, Aβ, Aβ Accumulation, Aβ-Plaques, Aβopathy, Amyloid Beta, Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, Amyloid-Related Imaging Abnormalities-Edema (ARIA-E), Amyloidopathy, Antibody-Based Immunotherapy Against Aβ, ARIA-E Episodes, Beta-Amyloid, Beta-Amyloid Plaques, Biogen, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Side-Effects, Drug Trials Failure Rate, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, Drugs for Treatment of Alzheimer’s Disease, Edema, β-Amyloid (Aβ) Accumulation, β-amyloid Deposition, Monoclonal Antibodies, Neurimmune, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Oedema, Phase 3 EMERGE Study, Phase 3 ENGAGE Study, Slowing of Cognitive Decline, Treatment of Alzheimer's Disease | Leave a comment

Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)

Posted on June 17, 2019 by Dementia and Elderly Care News

Summary A recent systematic review examines biomarkers, as strictly defined, for neurodegenerative diseases. “Vast improvements in neuroimaging techniques have led to newly discovered biomarkers and diagnostics”. p.5 Behavioural biomarkers are mentioned hardly at all. Full Text Link Reference Maclin, JMA. … Continue reading →

Posted in Alzheimer’s Research UK, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Personalisation, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged 18F-florbetaben, 18F-flutemetamol, 18Fflorbetapir, Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease Biomarkers, Alzheimer’s Research UK (ARUK), Amyloid and Tau PET, APOE e4 (Apolipoprotein E e4), Apolipoprotein E (APOE) e4 Allele, Behavioural Biomarkers, Beta-Amyloid PET Imaging, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Canonical Syndromes of Primary Progressive Aphasia: Non-Fluent / Agrammatic Variant (nfvPPA), Canonical Syndromes of Primary Progressive Aphasia: Semantic Variant (svPPA), Carbon-11 Pittsburgh Compound-B (C-PIB) Radioisotope Tracer, Cerebral Metabolic Rate for Glucose (CMRgl), Cerebrospinal Fluid (CSF) Biomarkers, Cerebrospinal Fluid and Serum MHPG, CMRgl Decline, Corticobasal Degeneration (CBD), CSF 3-methoxy-4-hydrox-yphenylglycol (MHPG), Dementia With Lewy Bodies (DLB), Differential Diagnosis, DLB: Dementia with Lewy Bodies, Docosahexaenoic Acid (DHA), Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Eicosapentaenoic Acid (EPA), Frontotemporal Dementia (FTD), α-Synuclein, Journal of Geriatric Care and Research (JGCR), Lewy Body Dementia (LBD), Magnetic Resonance Imaging (MRI), Medial Temporal Lobe Atrophy (MTA), Medial Temporal Lobes (MTL), Metabolic Syndrome (MetS), MRI Brain Imaging, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuroimaging, Neuroimaging in Dementia Diagnosis, Non-Invasive Biomarkers, Pick’s Disease (Frontotemporal Dementia), Positron Emission Tomography (PET), Preclinical Alzheimer's Disease, Primary Progressive Aphasia (PPA), Progressive Supranuclear Palsy (PSP), Rapid Screening, Screening for Dementia, Sea Hero Quest (SHQ) Game, Sea Hero Quest VR, Tau PET, Timely Diagnosis, VaD: Vascular Dementia, Variants of Primary Progressive Aphasia (PPA), Vascular Dementia, [18F]THK5351 | Leave a comment

Time for a Complete Reset in Alzheimer’s Disease / Dementia Drugs Research: Never Too Late? (BBC News / Brain / NHS Digital)

Posted on May 1, 2019 by Dementia and Elderly Care News

Summary A new type of dementia, previously misdiagnosed as Alzheimer’s Disease, has been discovered to be prevalent in the oldest of old persons. Perhaps a third of elderly people earlier thought to have Alzheimer’s Disease may have had Limbic-predominant age-related … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Amnestic MCI, Australia, Austria, Bazian, BBC Health News, Behind the Headlines, Brain (Journal), Central Clinical School Faculty of Medicine and Health (Sydney Australia), Clinical and Neurocognitive Features of LATE, Consensus Guidelines for LATE-NC Staging, Consensus Proposed LATE-NC TDP-43 Stages, Dementia-Related Misdiagnosis, Differential Diagnosis, Drug Trials, Drug Trials Failure Rate, Emory University (Atlanta), FTLD-TDP: Frontotemporal Lobar Degeneration With TDP-43 Proteinopathy, Harvard University, Hippocampal Atrophy, Illinois Institute of Technology, Institute of Neurology: Medical University of Vienna, Japan, LATE Biomarkers, LATE Neuropathological Change (LATE-NC), LATE Working Group, Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE), Mayo Clinic (Jacksonville), Mayo Clinic: Rochester, Medical University of Vienna, Misdiagnosis, Misdiagnosis (Potential), Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuropathology, Neuropathology in FTLD-tau and FTLD-TDP, Newcastle University, NHS Digital (Formerly NHS Choices), Oldest Old, Oldest Old Age, Oldest People With Dementia, Prevalence of Dementia in Oldest Old, Public Health Impact of LATE, Recommendations for Routine Autopsy Evaluation and Classification of LATE-NC, Rush University Medical Center, Stanford University, Subtypes of Dementia, Sweden, TDP-43 Protein, TDP-43 Proteinopathy, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, United States, University of California, University of Cambridge, University of Kentucky, University of Minnesota, University of Pennsylvania, University of Southern California, University of Sydney Brain and Mind Centre, University of Texas Southwestern Medical Center, University of Washington, Uppsala University, USA | Leave a comment

Optometric and Ophthalmological Tests for Visual Symptoms of Posterior Cortical Atrophy (BMJ Open)

Posted on April 5, 2019 by Dementia and Elderly Care News

Summary Research by the College of Optometrists on Posterior Cortical Atrophy (PCA) has investigated the suitability of certain vision assessment tests to help differentiate between cortical and optical / ocular causes of visual impairment. An awareness of PCA helps to … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Quick Insights, UK | Tagged Acalculia, Agraphia, Balint’s Syndrome, BMJ Open, BMJ Publishing Group Ltd, College of Optometrists, Dementia Research Centre: University College London, Department of Research: College of Optometrists, Fragmented Images or Letters, Fragmented Letters Test, Gerstmann’s Syndrome, Identification of Cortical Perceptual Problems, Institute of Neurology: University College London, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Oculomotor Apraxia, Optometric and Ophthalmological Tests for Posterior Cortical Atrophy, Posterior Cortical Atrophy, Posterior Cortical Atrophy (PCA), Progressive Visual Dysfunction, Queen Square Screening Test for Cognitive Deficits (The Green Book), Queen Square Screening Test for Visual Deficits, Queen Square Screening Test for Visual Deficits (The Blue Book), Rare Dementia Support (London), Rare Dementia Support PCA Support Group, Rare Dementias, Reduced Effective Field of Vision, Simultanagnosia, Snellen Letter Chart, UCL PCA Support Group, University College London (UCL), University College London’s Queen Square Neurology Centre, Vision Assessment Tests, Visual Dysfunction in Posterior Cortical Atrophy, Visual Symptoms of Posterior Cortical Atrophy | Leave a comment

Tag Archives: Neurodegenerative Diseases

More on the Possible Role of Neuroinflammation in Frontotemporal Dementia (Bazian / Brain)

Cerebral Amyloid Angiopathy (JGCR)

Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)

Optometric and Ophthalmological Tests for Visual Symptoms of Posterior Cortical Atrophy (BMJ Open)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites